Placeholder photo for Bilal Hafeez

Bilal Hafeez

Assistant Professor of Pharmacology

Biography

Dr. Bilal Bin Hafeez is a tenure-track assistant professor in the Department of Pharmaceutical Sciences at Ä¢¹½¶ÌÊÓƵ. He earned his M.S. and Ph.D. in toxicology from Hamdard University, New Delhi, India, followed by postdoctoral training at Roswell Park Cancer Institute, Buffalo, New York. He subsequently held progressive research and faculty appointments at Case Western Reserve University, the University of Wisconsin-Madison, the University of Tennessee Health Science Center and the University of Texas Rio Grande Valley School of Medicine before joining SDSU in 2025.

With over 70 peer-reviewed publications, two book chapters and an h-index of 46, Hafeez has built a distinguished career in cancer biology, molecular therapeutics, and the development of transgenic and knockout mouse models for preclinical studies. His research has been funded by the National Institutes of Health and the Texas Cancer Prevention and Ä¢¹½¶ÌÊÓƵ Institute, and he serves as associate editor for Cell Biology International and Frontiers in Oncology. He is a recipient of the Outstanding Ä¢¹½¶ÌÊÓƵer Award at the Asia International Ä¢¹½¶ÌÊÓƵ Award 2023.

At SDSU, Hafeez's research focuses on the role of dysregulated ribosome biogenesis in gastrointestinal and prostate cancers, with the goal of developing innovative therapeutic strategies to overcome chemotherapy and immunotherapy resistance in solid tumors. His laboratory recently made a significant discovery demonstrating that targeting RPA194 — the catalytic subunit of RNA polymerase I — induces ubiquitin-mediated degradation of mutant p53 and potently suppresses pancreatic tumor growth. Complementing his research, he teaches advanced pharmacology and pathophysiology courses to Pharm.D. and Ph.D. students, bridging laboratory discovery with the clinical knowledge essential to training future leaders in the pharmaceutical and biomedical sciences.

Education

  • M.S. in toxicology | Hamdard University, Delhi, India | 1998
  • Ph.D. in toxicology | Hamdard University, Delhi, India | 2002
  • Postdoctoral Fellow | Roswell Park Cancer Institute, Buffalo, New York | 2003-04
  • Postdoctoral Fellow | University of Wisconsin-Madison, Madison, Wisconsin | 2005-08

Academic and Professional Experience

Academic Interests

Hafeez is deeply committed to the education and mentorship of the next generation of biomedical scientists, clinicians and pharmaceutical professionals across multiple training levels. At SDSU College of Pharmacy, he currently teaches Doctor of Pharmacy students in PHA 353 and PHA 453 — Pharmacology, Pathophysiology, and Toxicology — delivering instruction on the pathophysiology of major cardiovascular diseases, the pharmacology of anticancer, antifungal, antiviral, antiparasitic and antihelminthic agents, and cancer immunotherapy, including checkpoint blockade, CAR-T cell therapy and cancer vaccines.

Academic Responsibilities
  • PHA 354: Pharmacology, Pathophysiology and Toxicology II to first-year Pharm.D. students
  • PHA 453: Pharmacology, Pathophysiology and Toxicology II to second-year Pharm.D. students
  • PHA 452: Pharmacology, Pathophysiology and Toxicology II to second-year Pharm.D. students
  • PHA 740: Advanced Concepts in Pharmacology to Ph.D. students
  • PUBH 767: Public Health Toxicology to MPH students
Committees and Professional Memberships

Committees

  • Department Graduate Student Search Committee

Professional Membership

  • American Association for Cancer Ä¢¹½¶ÌÊÓƵ (active member)
  • Indian Association for Cancer Ä¢¹½¶ÌÊÓƵ (life member)

Professional Service

National Scientific Panels:

  • 2022: Ad Hoc Member, Scientific Review Committee, Pilot Grant, Texas Academy of Science Student Ä¢¹½¶ÌÊÓƵ Proposal.
  • 2024: Ad Hoc Member, Scientific Review Committee, Advancing Therapeutic A Study Section, National Institutes of Health.
  • 2024: Ad Hoc Member, Scientific Review Committee, NIH/CSR Study Section [ZRG1 CTH-E (11)].
  • 2025: Ad Hoc Member, Scientific Review Committee, Advancing Therapeutic A Study Section, NIH.
  • 2025: Ad Hoc Member Scientific Review Committee, New Jersey Commission on Cancer Ä¢¹½¶ÌÊÓƵ, New Jersey Department of Health.
  • 2025: Ad Hoc Member, Scientific Review Committee, Pilot Grants Program, Institute for Clinical and Translational Ä¢¹½¶ÌÊÓƵ, University of Maryland, Baltimore.
  • 2025: External Scientific Reviewer for Team Scientist Grant Award Proposals, Southern Illinois University, School of Medicine, Springfield.
  • 2026: Ad Hoc Member Scientific Review Committee, New Jersey Commission on Cancer Ä¢¹½¶ÌÊÓƵ, New Jersey Department of Health.

International Scientific Panels:

  • 2025: Served as Scientific Reviewer in Scientific Promotion System, King Abdul Aziz University, Saudi Arabia.
  • 2025: Served as Scientific Reviewer in Czech Science Foundation Grant, Czech Republic.

Journals Editorship:

  • Associate Editor of Cell Biology International (2021-present)
  • Associate Editor of Frontiers in Oncology (2022-present)

Editorial Board Member:

  • Cancer and Clinical Ä¢¹½¶ÌÊÓƵ
  • Journal of Endocrine Disorders
  • Indian Journal of Pathology and Oncology
Extension Responsibilities
  • Graduate faculty representative
Work Experience
  • Assistant Scientist: Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison (January 2009-Februay 2011)
  • Associate Scientist: Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison (March 2011-July 2015)
  • Associate Scientist: Department of Pharmaceutical Sciences, University of Tennessee Health Science Center (August 2015-November 2016)
  • Assistant Professor (Nontenure-Track), Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis (December 2016-May 2019)
  • Assistant Professor (Tenure-Track): Department of Medicine and Oncology ISU, School of Medicine, University of Texas Rio Grande Valley (June 2019-August 2025)
  • Assistant Professor (Tenure-Track): Department of Pharmaceutical Science, Ä¢¹½¶ÌÊÓƵ (September 2025-present)

Ä¢¹½¶ÌÊÓƵ and Scholarly Work

Areas of Ä¢¹½¶ÌÊÓƵ

Hafeez's research program focuses on elucidating the molecular mechanisms by which dysregulated ribosome biogenesis drives the initiation, progression and therapy resistance of solid tumors, with a primary focus on gastrointestinal cancers — particularly pancreatic and liver cancer — and prostate cancer. His laboratory employs a multidisciplinary approach integrating transgenic and knockout mouse models, advanced molecular biology, and preclinical drug evaluation to identify and validate ribosome biogenesis components as novel diagnostic biomarkers and actionable therapeutic targets.

A cornerstone discovery of his research group demonstrated that pharmacological targeting of RPA194, the catalytic subunit of RNA polymerase I, induces ubiquitin-mediated degradation of oncogenic mutant p53 protein and potently suppresses pancreatic tumor growth — findings published in Molecular Cancer Therapeutics (2026).

Hafeez's overarching translational goal is to develop new molecular targets and innovative therapeutic strategies, including small-molecule inhibitors of ribosome biogenesis components with direct implications for improving clinical outcomes in patients.

Awards and Honors
  • Senior Ä¢¹½¶ÌÊÓƵ Fellowship, Central Council for Ä¢¹½¶ÌÊÓƵ on Unani Medicine, Government of India. (1998)
  • Senior Ä¢¹½¶ÌÊÓƵ Fellowship, Council for Scientific and Industrial Ä¢¹½¶ÌÊÓƵ, New Delhi, Ministry of Health and Welfare, Government of India. (2000)
  • Investigator Award, Santa Cruz Biotechnology. (2012)
  • Outstanding Ä¢¹½¶ÌÊÓƵer Award, Asia International Ä¢¹½¶ÌÊÓƵ Award Tamil Nadu. (2023)
Grants
  1. NIH/SC1 GM140982-01 (40% Effort)

Title: Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer

Role: Principal Investigator

Total costs: $1.45 million

Grant Period: Sept. 1, 2021-March 31, 2026

  1. CPRIT Pilot Study Award 2023 (10% Effort)

Award Mechanism: TRECPSA

Title: Role of transcription factor UBTF in pancreatic cancer

Role: Principal Investigator

Total costs: $200,000

Grant Period: Aug. 1, 2023-Aug. 31, 2025

  1. NIH/RO1 CA210192-01

Title: Targeted nanotherapy for pancreatic cancer treatment

Role: Co-Investigator (10% Effort)

Grant Period: Sept. 1, 2017-Aug. 31, 2023

  1. King Saudi Arabia International Collaboration Grant

Title: Genetic polymorphism of IL-6, IL-8 and CRP genes as prognostic biomarkers for chemotherapeutic response in Saudi Arabia and American ovarian patients

Role: Co-Principal Investigator

Total Cost: $75,000

Grant Period: Aug. 1, 2020-Aug. 31, 2023

  1. UTHSC Seed Grant

Title: Alpha-mangostin: A novel therapeutic agent for pancreatic cancer treatment

Role: Principal Investigator

Total Cost: $35,000

Grant Period: June 1, 2017-May 30, 2019

  1. Dean Seed Grant (MPI)

Title: Targeting ribosome biogenesis and tumor microenvironment for pancreatic cancer treatment

Role: Principal Investigator

Total Cost: $15,000

Grant Period: Nov. 1, 2018-Oct. 31, 2019

  1. UTRF grant

Total Cost: $15,000

Role: Co-investigator

Grant Period: Jan. 1, 2019-Oct. 30, 2019

Publications

2026

  1. Ahmad M., Alvi S.S., Ahsan H., Perez C., Massey A., Kashyap V.K., Chauhan N., Anning E., Bangash A., Tripathi M., Kim D.J., Sahoo N., Khan M., Chauhan S.C., *Hafeez B.B. Ubiquitination of oncogenic mutant p53 via attenuation of ribosome biogenesis machinery effectively inhibits pancreatic tumor growth. Molecular Cancer Therapeutics. Feb. 4, 2026; 25(2):257-271. PMID: 41053975.

2025

  1. Ahmad M., Alvi S.S., Dhasmana A., Kim D.J., Yallapu M.M., Chauhan S.C., *Hafeez B.B. Mitochondrial ribosomal protein MRPL3: An early diagnostic biomarker and possible molecular target in pancreatic cancer. Translational Oncology May 29; 58:102432, 2025. PMID: 40446627.
  2. Asare O., Shim L., Lee C., Delgado J., Quales N., Zavala K., Park J., Hafeez B.B., Cho Y., Chauhan S.C., Kim D.J. Loss of TC-PTP in keratinocytes leads to increased UVB-induced autophagy. Cell Death Discovery Feb. 28, 2025; 11(1):80. PMID: 40021617.

2024

  1. Kashyap V.K., Nagesh P.K.B., Singh A.K., Massey A., Darkwah G.P., George A., Khan S., Hafeez B.B., Zafar N., Kumar S., Sinha N., Yallapu M.M., Chauhan N., Chauhan S.C. Curcumin attenuates smoking and drinking activated NF-κB/IL-6 inflammatory signaling axis in cervical cancer. Cancer Cell International. Oct. 20, 2024; 24(1):343. PMID: 39428480.
  2. Bangash A., Alvi S., Bangash M., Ehsan H., Ahmad M., Bansal D., Khan S., Shareef R., Chauhan S.C., *Hafeez B.B. Honey targets ribosome biogenesis components to suppress the growth of human pancreatic cancer cells. Cancers Oct. 9, 2024; 16(19):3431. PMID: 39410048.
  3. Setua S., Shabir S., Shaji P., Bulnes A.M., Dhasmana A., Holla S., Mittal N.K., Sahoo N., Saini T., Giorgianni F., Sikander M., Massey A.E., Hafeez B.B., Tripathi M., Diego V., Jaggi M., Yu J., Zafar N., Yallapu M.M., Behrman S.W., Khan S., Chauhan S.C. Exosome derived from tumor adjacent fibroblasts efficiently target pancreatic cancer. Acta Pharmaceutica Sinica B. 2024 July; 14(7):3009-3026. PMID: 39027237.

2023

  1. Doxtater K., Tripathi M.K., Sekhri R., Hafeez B.B., Khan S., Zafar N., Yallapu M.M., Jaggi M. and Chauhan S.C. MUC13 drives cancer aggressiveness and metastasis through the YAP1-dependent pathway. Life Science Alliance (EMBO), Oct. 4, 2023; 6(12): e202301975. PMID:37793774.
  2. Asif M., Alvi S.S., Azaz T., Khan A.R., Tiwari B., Hafeez B.B., Nasibullah M. Novel functionalized spiro [Indoline-3,5'-pyrroline]-2,2'dione derivatives: Synthesis, characterization, drug-likeness, ADME and anticancer potential. International Journal of Molecular Sciences. April 15, 2023; 24(8):7336. PMID: 37108498. (Hafeez B.B. and Nasibullah M. are corresponding authors).
  3. Haque A., Baig G.A., Alshawli A.S., Sait K.H.W., Hafeez B.B., Tripathi M.K., Alghamdi B.S., Mohammed Ali HSH, Rasool M. Interaction analysis of MRP1 with anticancer drugs used in ovarian cancer: In silico approach. Life (Basel). March 7, 2022; 12(3):383.
  4. Asare O., Ayala Y., Hafeez B.B., Ramirez-Correa G.A., Cho Y.Y., Kim D.J. . Photochemistry Photobiology. 2023 March; 99(2):344-355. PMID: 36029171.
  5. Hafeez B.B., Alvarado E.W., Kim D.J. . Photochemistry Photobiology. 2023 March; 99(2):874-877. PMID: 36151964.

2022

  1. Ahmad M., Dhasmana A., Harne P.S., Zamir A., Hafeez B.B.* Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes? Seminars in Cancer Biology 2022 November; 86(Pt 3):1175-1185. PMID: 35189322.
  2. Haque A., Baig G.A., Alshawli A.S., Sait K.H.W., Hafeez B.B., Tripathi M.K., Alghamdi B.S., Mohammed Ali H.S.H., Rasool M. Interaction analysis of MRP1 with anticancer drugs used in ovarian cancer: In silico approach. Life (Basel). March 7, 2022; 12(3):383.
  3. Chaib M., *Hafeez B.B., Mandil H., Deidre D., Pingili A.K., Sikander M., Kashyap V.K., Tripathi M.K., Khan S., Behrman S., Yallapu M.M., Jaggi M., Makowski L. and Chauhan S.C. . Communications Biology. Nov. 4, 2022; 5(1):1181. PMID: 36333531. (Hafeez B.B. and Chauhan S.C. are corresponding authors).

2021

  1. Kumari S., Sikander M., Malik S., Tripathi M.K., Hafeez B.B., Yallapu M.M., Chauhan S.C., Khan S., Jaggi M. Steviol represses glucose metabolism and translation initiation in pancreatic cancer cells. Biomedicines. Dec. 2, 2021; 9(12):1814. PMID: 34944630.
  2. Massey A.E., Malik S., Sikander M., Doxtater K.A., Tripathi M.K., Yallapu M.M., Jaggi M., Chauhan S.C., Hafeez B.B.* Clinical implications of exosomes: Targeted drug delivery for cancer treatment. International Journal of Molecular Sciences. May 17, 2021; 22(10):5278). PMID: 34067896. (*Corresponding author).

2020

  1. Shetty A., Nagesh P.K.B., Setua S., Hafeez B.B., Jaggi M., Yallapu M.M., Chauhan S.C. Novel paclitaxel nanoformulation impairs de novo lipid synthesis in pancreatic cancer cells and enhances gemcitabine efficacy. ACS Omega. April 13, 2020; 5(15):8982-8991.
  2. Kashyap V.K., Dan N., Chauhan N., Wang Q., Setua S., Nagesh P.K.B., Malik S., Batra V., Yallapu M.M., Miller D.D., Li W., Hafeez B.B., Jaggi M., Chauhan S.C. VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway. Cancer Letters. Feb. 1, 2020; 470:64-74. PMID: 31809801.

2019

  1. Khan S., Setua S., Kumari S., Dan N., Massey A., Hafeez B.B., Yallapu M.M., Stiles Z.E., Alabkaa A., Yue J., Ganju A., Behrman S., Jaggi M., Chauhan S.C. . Biomaterials. 2019 July; 208:83-97. PMID: 30999154.
  2. Chauhan N., Maher D.M., Yallapu M.M., Hafeez B.B., Singh M.M., Chauhan S.C., Jaggi M. . Scientific Reports. July 29, 2019; 9(1):10917. PMID: 31358785.
  3. Chauhan N., Maher D.M., Hafeez B.B., Mandil H., Singh M.M., Yallapu M.M., Jaggi M., Chauhan S.C. . International Journal of Nanomedicine. Sept. 3, 2019; 14:7107-7121. PMID: 31564868.
  4. Messy A., Sikander M., Chauhan N., Kumari S., Setua S., Shetty A.B., Mandil H., Kashyap V.K., Khan S., Jaggi M., Yallapu M.M., *Hafeez B.B., Chauhan S.C. Next-generation Paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine. June 4, 2019; 20:102027. PMID: 31170509. (*Co-first author).
  5. Kashyap V.K., Wang Q., Setua S., Nagesh P.K.B., Chauhan N., Kumari S., Chaudhury P., Miller D.D., Yallapu M.M., Li W., Jaggi M., *Hafeez B.B., Chauhan S.C.* Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. Journal of Experimental and Clinical Cancer Ä¢¹½¶ÌÊÓƵ 2019; 38:29. PMID: 30674344. (*Co-corresponding author).

2018

  1. Nagesh P.K.B., Chowdhury P., Hatami E., Boya V.K.N., Kashyap V.K., Khan S., Hafeez B.B., Chauhan S.C., Jaggi M., Yallapu M.M. . Cancers (Basel). Aug. 25, 2018;10(9).
  2. Ganju A., Chauhan S.C., Hafeez B.B., Doxtater K., Tripathi M.K., Zafar N., Yallapu M.M., Kumar R., Jaggi M. Protein kinase D1 regulates subcellular localization and metastatic function of metastasis-associated protein 1. British Journal of Cancer. Feb. 20, 2018; 118(4):587-599. PMID: 29465084.
  3. Chowdhury P., Prashanth K.B. Nagesh, Sheema Khan, Hafeez B.B., Chauhan S.C., Jaggi M., Yallapu M.M. . Acta Pharmaceutica Sinica B, 2018 July; 8(4):602-614. PMID: 30109184.

2017

  1. Hafeez B.B., Ganju A., Sikander M., Kashyap V.K., Chauhan N., Malik S., Massey A.E., Tripathi M.K., Halaweish F.T., Zafar N., Singh M.M., Yallapu M.Y., Chauhan S.C., Jaggi M. Ormeloxifene suppresses prostate tumor growth and metastatic phenotypes via inhibition of oncogenic β-catenin signaling and EMT progression. Molecular Cancer Therapeutics. 2017 October; 16(10):2267-2280. PMID: 28615299.
  2. Chowdhury P., Roberts A.M., Khan S., Hafeez B.B., Chauhan S.C., Jaggi M., Yallapu M.M. . Drug Discovery Today. 2017 August; 22(8):1233-1241. PMID: 28526660.
  3. Ganju A., Khan S., Hafeez B.B., Behrman S.W., Yallapu M.M., Chauhan S.C., Jaggi M. . Drug Discovery Today. 2017 February; 22(2):424-432. PMID: 27815139.
  4. Khan S., Sikander M., Ebeling M.C., Ganju A., Kumari S., Yallapu M.M., Hafeez B.B., Ise T., Nagata S., Zafar N., Behrman S.W., Wan J.Y., Ghimire H.M., Sahay P., Pradhan P., Chauhan S.C., Jaggi M. . Oncogene. Jan. 26, 2017; 36(4):491-500. PMID: 27321183.

2016

  1. Sikander M.,* Hafeez B.B.,* Malik S., Alsayari A., Halaweish F.T., Yallapu M.M., Chauhan, S.C., Jaggi M. Cucurbitacin D exhibits potent anticancer activity in cervical cancer. Scientific Reports. Nov. 8, 2016; 6:36594. PMID: 27824155. (*Co- first author).
  2. Nagesh P.K.B., Johnson N.R., Boya V.K.N., Chowdhury P., Othman S.F., Khalilzad-Sharghi V., Hafeez B.B., Ganju A., Khan S., Behrman S.W., Zafar N., Chauhan S.C., Jaggi M., Yallapu M.M. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids and Surfaces B: Biointerfaces. Aug. 1, 2016; 144:8-20. PMID: 2705827.
  3. Hafeez B.B., Meske L., Singh A., Zhong W., Powers P., John M., Griep A.E., Verma A.K. . Oncotarget. May 31, 2016; 7(22):33069-80. PMID: 27102301.
  4. Singh A., Willems E., Hafeez B.B., Ong I.M., Mehta S.L., Verma A.K. Ultraviolet radiation-induced tumor necrosis factor alpha, which is linked to the development of cutaneous SCC, modulates differential epidermal microRNAs expression. Oncotarget. April 5, 2016; 7(14):17945-56 PMID: 2691845.

2015

  1. *Hafeez B.B., Fischer J.W., Singh A., Zhong W., Mustafa A., Meske L., Sheikhani M.O., Verma A.K.. Cancer Prevention Ä¢¹½¶ÌÊÓƵ. 2015 May; 8(5):375-86. PMID: 25627799. (*Corresponding author).
  2. Singh A., Bauer S., Sand J.M., Hafeez B.B., Meske L. and Verma A.K. Topically applied Hsp90 inhibitor 17AAG inhibits ultraviolet radiation-induced cutaneous wrinkles and squamous cell carcinomas. Journal of Investigative Dermatology. 2015 April; 135(4):1098-1107. PMID: 25337691.

2014

  1. *Hafeez B.B., Mustafa A., Fischer J.W., Singh A., Zhong W., Sheikhani M.O., Meske L., Havighurst T., Kim K., Verma A.K. Alpha-mangostin, a dietary antioxidant inhibits the growth of pancreatic cancer cells xenograft tumors in athymic nude mice. Antioxidant and Redox Signaling. Aug. 10, 2014; 21(5):682-99. PMID: 24295217 (*Corresponding author).

2013

  1. Singh A., Sand J.M., Heninger E., Hafeez B.B., Verma A.K. Protein kinase Cε, which is linked to ultraviolet radiation-induced development of squamous cell carcinomas, stimulates rapid turnover of adult hair follicle stem cells. Journal of Skin Cancer. 2013, 2013:452425. PMID: 23738074.
  2. *Hafeez B.B., Zhong W., Fischer J.W., Mustafa A., Shi X., Meske L., Hong H., Cai W., Havighurst T., Kim K., Verma A.K. Plumbagin inhibits human prostate cancer PC3M luciferase cells derived xenograft tumors and metastasis in an orthotropic xenograft mouse model. Molecular Oncology. 2013, 7(3):428-39. PMID: 23273564 (*Corresponding author).

2012

  1. Hafeez B.B., Fischer J., Jamal S., Mustafa A., Verma A.K. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers. Carcinogenesis 2012, 33(12):2586-92. PMID: 22976928. (*Corresponding author).
  2. *Hafeez B.B., Jamal S., Fischer J., Mustafa A., Verma A.K. Plumbagin, a plant based naphthoquinone inhibits the growth of pancreatic cancer cells in vitro and in vivo via targeting EGFR, Stat3 and NF- kB signaling networks. International Journal of Cancer. 2012, 131(9):2175-86. PMID: 22322442. (*Corresponding author).
  3. Sand J.M., Hafeez B.B., Jamal M.S., Witkowsky O., Siebers E.M., Fischer J., Verma A.K. . Carcinogenesis 2012, 33(1):184-90. PMID: 22072620.
  4. Sand J.M., Bin Hafeez B., Aziz M.H., Siebers E.M., Dreckschmidt N.E., Verma A.K. Ultraviolet radiation and 12-O-tetradecanoylphorbol-13-acetate-induced interaction of mouse epidermal protein kinase Cε with Stat3 involve integration with ERK1/2. Molecular Carcinogenesis 2012 April; 51(4):291-302. PMID: 21480396.

2011

  1. Asim M., Hafeez B.B., Siddiqui I.A., Gerlach C., Patz M., Mukhtar H., Baniahmad A. LCoR acts as a novel androgen receptor corepressor inhibits prostate cancer growth, and its functionality is inactivated by the Src kinase. Journal of Biological Chemistry 2011, 6 (43):37108-17. PMID: 21856747.
  2. Hafeez B.B., Zhong W., Weichert J., Dreckschmidt N.E., Jamal M.S., Verma A.K. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Ä¢¹½¶ÌÊÓƵ 2011.71(6);2318-27. PMID: 21406403.
  3. Siddiqui I.A., Asim M., Hafeez B.B., Adhami V.M., Tarapore R.S., Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB Journal. 2011, 25(4);1198-207. PMID: 21177307.

2010

  1. Prasad A.S., Mukhtar H., Beck F.W., Adhami V.M., Siddiqui I.A., Din M., Hafeez B.B., Kucuk O. Dietary zinc and prostate cancer in the TRAMP mouse model. Journal of Medicinal Food 2010, 13(1);70-6. PMID: 20136438.
  2. Aziz M.H., Hafeez B.B., Sand J.M., Pierce D.B., Aziz S.W., Dreckschmidt N.E., Verma A.K. Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2 and ERK1/2). Oncogene May 27, 2010; 29(21):3100-9. PMID: 20228845.

2009

  1. Saleem M., Murtaza I., Tarapore R., Suh Y., Adhami V.M., Johnson J.J., Siddiqui I.A., Khan N., Asim M., Hafeez B.B., Shekhani M.T., Li B., Mukhtar H. Lupeol inhibits proliferation of human prostate cancer cells y targeting {beta}-catenin signaling. Carcinogenesis 2009, 30(5);808-17. PMID: 19233958.
  2. Adhami V.M., Siddiqui I.A., Sarfaraz S., Khwaja S.I., Hafeez B.B., Ahmad N., Mukhtar H. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clinical Cancer Ä¢¹½¶ÌÊÓƵ 2009, 15(6);1947-53. PMID: 19276266.
  3. Siddiqui I.A., Adhami V.M., Bharali D.J., Hafeez B.B., Asim M., Khwaja S.I., Ahmad N., Cui H., Mousa S.A., Mukhtar H. (2009). Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol Epigallocatechin-3-Gallate. Cancer Ä¢¹½¶ÌÊÓƵ 2009, 69(5);1712-6. PMID: 19223530.
  4. Hafeez B.B., Adhami V.M., Asim M., Imtiaz I.A., Saleem M., Kumar M.R. Bhat, Din M., Sataluri V.S., Mukhtar H. . Clinical Cancer Ä¢¹½¶ÌÊÓƵ 2009, 15(2);452-9. PMID: 19147749.
  5. Murtaza I., Saleem M., Adhami V., Hafeez B.B., Mukhtar H. Suppression of cFLIP by Lupeol a dietary triterpene is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Ä¢¹½¶ÌÊÓƵ 2009, 69(3):1156-65. PMID: 19176377.
  6. Murtaza I., Adhami V.M., Hafeez B.B., Saleem M. and Mukhtar H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3 mediated inhibition of NF-κB. International Journal of Cancer 2009, 125(10):2465-73.
  7. Aziz M.H., Hafeez B.B., Sand J.M., Pierce D.B., Aziz S.W., Dreckschmidt N.E. and Verma A.K. Protein kinase C epsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression and cell invasion in various human cancer cell lines via integration with ERK1/2. Oncogene 2009; 27;29(21):3100-9.

2008

  1. Saleem M., Maddodi N., Zaid M.A., Khan N., Hafeez B.B., Asim M., Suh Y., Yun J., Setaluri V., Mukhtar H. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clinical Cancer Ä¢¹½¶ÌÊÓƵ 2008, 14: 2119-27. PMID: 18381953.
  2. Asim M., Siddiqui I.A., Hafeez B.B., Baniahmad A., Mukhtar H. Src Kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008, 27(25):3596-604. 27(14):2055-63. PMID: 18223692.
  3. Siddiqui I.A., Shukla Y., Adhami V.M., Sarfaraz S., Asim M., Hafeez B.B., Mukhtar H. Suppression of NF-kappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharmaceutical Ä¢¹½¶ÌÊÓƵ 2008, 25(9): 2135-42. PMID: 18317887.
  4. Hafeez B.B., Asim M., Siddiqui I.A., Adhami V.A., Ahmad A., Jakka S.A., Baniahmad A. and Mukhtar H. Delphinidin, a dietary anthocyanidin in pigmented fruits and vegetables: A new weapon to blunt prostate cancer growth. Cell Cycle 2008, 7(21):3320-6. PMID: 18948740.
  5. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., Mukhtar H. Green tea polyphenols EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008, 27(14):2055-63. PMID: 17998943.

2006

  1. Saleem M., Kweon M.H., Johnson J.J., Adhami V.M., Elcheva I., Khan N., Hafeez B.B., Bhat K.M., Sarfaraz S., Reagan-Shaw S., Spiegelman V.S., Setaluri V., Mukhtar H. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proceeding of the National Academy of Sciences (PNAS) USA 2006, 103; 14825-30.
  2. Ewens A., Luo L., Berleth E., Alderfer J., Wollman R., Hafeez B.B., Kanter P., Mihich E., Ehrke M.J. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Ä¢¹½¶ÌÊÓƵ 2006, 66; 5419-26. PMID: 16707470.
  3. Hafeez B.B., Ahmed S., Naizen W., Haqqi T.M. Green tea polyphenols-induced apoptosis in human osteosarcoma SAOS-2 cells involves a caspase-dependent mechanism with down-regulation of nuclear factor-kappaB. Toxicology and Applied Pharmacology 2006, 216;11-9.

2005

  1. Ahmed S., Naizen W., Hafeez B.B., Haqqi T.M. Punica granatum L extracts inhibits IL-1 beta induced expression of matrix metalloproteinases by inhibiting the activation of the mitogen activated protein kinesis and nuclear factor-kB activity in human chondrocytes in vitro. Journal of Nutrition 2005, 135; 2096-102.

2003

  1. Pandey S., Parvez S., Sayeed I., Haque R., Hafeez B.B., Raisuddin S. Biomarkers of oxidative stress: A comparative study of river Yamuna fish Wallago attu (Bloch and Schneider.) Science of the Total Environment 2003, 309:105-115. PMID: 12798096.
  2. Parvez S., Sayeed I., Pandey S., Ahmad A., Ahmad A., Hafeez B.B., Haque R., Raisuddin S. Modulatory effect of copper on nonenzymatic antioxidants in freshwater fish Channa punctatus (Bloch.). Biological Trace Element Ä¢¹½¶ÌÊÓƵ 2003, 93; 237-48.
  3. Sayeed I., Parvez S., Pandey S., Hafeez B.B., Haque R., Raisuddin S. Oxidative stress biomarkers of exposure to deltamethrin in freshwater fish Channa punctatus Bloch. Ecotoxicology and Environmental Safety 2003, 56; 295-301. PMID: 12927561.
  4. Haque R., Hafeez B.B., Parvez S., Pandey S., Saeed I., Ali. M, Raisuddin S. Aqueous extract of walnut (Juglans regia L.) protects mice against cyclophosphamide induced biochemical toxicity. Human and Experimental Toxicology 2003, 22; 473-480. PMID: 14580007.
  5. Hafeez B.B., Haque R., Parvez S., Pandey S., Saeed I., Raisuddin S. Immunomodulatory effect of Trigonella foenum-graecum in mice. International Immunopharmacology 2003, 3; 257-265. PMID: 12586606.

2001

  1. Pandey S., Ahmad I., Parvez S., Hafeez B.B., Haque R., Raisuddin S. Effect of endosulfan on antioxidants of freshwater fish Channa punctatus Bloch.1. Protection against lipid peroxidation in liver by copper preexposure. Archives of Environmental Contamination and Toxicology 2001, 41; 345-352. PMID: 11503072.
  2. Haque R., Hafeez B.B., Ahmad I., Parvez S., Pandey S., Raisuddin S. Immunomodulatory and glutathione inducing effects of Emblica officinalis Gaertn in cyclophosphamide-treated mice. Human and Experimental Toxicology 2001, 20; 643-650. PMID: 11936579.
  3. Hafeez B.B., Ahmad I., Haque R., Raisuddin. S. Protective effect of Cassia occidentalis L. on cyclophosphamide-induced suppression of humoral immunity in mice. Journal of Ethnopharmacology 2001, 75; 13-18. PMID: 11282437.

Book Chapters:

  1. Ahmad S., Hafeez B.B. and Haqqi T.M. Green Tea and the prevention of arthritis. Protective Effects of Tea on Human Health, Volume1, Editor: Jain N.K., Siddiqi M.A. and Weisburger J.H. 158-171, 2006.
  2. Hafeez B.B., Park E., Chun K.S., Cho Y.Y., Kim D.J. Regulation of apoptosis during environmental skin tumor Initiation. Open Access book, "Regulation and Dysfunction of Apoptosis" edited by Yusuf Tutar. Intech Open London: 5 Princes Gate Court, London, SW7 2QJ, UK +44 20 8089 5702. 2021.
Mailing Address:
Avera Health & Science 263
Pharmaceutical Sciences-Box 2202C
University Station
Brookings, SD 57007
Office Location:
Avera Health and Science Center
Room 263
Back to Directory
Related Links
Associated Areas
Dean Hansen talking with students
College of Pharmacy and Allied Health Professions
Graduate student and faculty using microscope
Department of Pharmaceutical Sciences